A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

134

Enrollment

INDUSTRY

Sponsor class

Stopped Primary endpoint not attained

Conditions

Dermatomyositis

Interventions

DRUG: human immunoglobulin G
DRUG: Placebo

Sponsor

CSL Behring